CPA
NUVB icon

Capital Performance Advisors’s Nuvation Bio NUVB Stock Holding History

Capital Performance Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-281
Closed -$643 – 1823
2024
Q3 		$643 Buy
+281
New +$857 ﹤0.01% 2131

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Capital Performance Advisors's NUVB Position: Q4 2024 in Review

Capital Performance Advisors sold out of Nuvation Bio (NUVB) in Q4 2024, closing a stake of 281 shares — an estimated $643 sold.

Capital Performance Advisors first reported a position in NUVB in Q3 2024 and held it in 1 quarter. The position peaked at $643 in Q3 2024. 160 funds tracked by Wall St. Rank hold NUVB as of Q4 2024.

  • Capital Performance Advisors reported no remaining Nuvation Bio position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 281 Nuvation Bio shares in Q4 2024, an estimated $643.
  • Capital Performance Advisors first reported a position in Nuvation Bio in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Nuvation Bio position peaked at $643 in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.